RxDoctor Payments Data

Omar Zantua, MD

Geriatric Medicine · Houston, TXNPI 1083675359

Payments from drug & device makers

$575in general payments, 2019–2025

Across 14 payments — averaging $41.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$283
  • Acadia Pharmaceuticals Inc$121
  • Alpha Cognition USA, Inc.$100
  • Sunovion Pharmaceuticals Inc.$27
  • Avanir Pharmaceuticals, Inc.$18
  • Lilly USA, LLC$15
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$47683%
  • Education$9917%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$575 in reported general payments places this provider in the 70th percentile of 275 geriatric medicine providers in Texas.

See all geriatric medicine providers in Texas

Medicare billing

Part B allowed, 2024
$170,458
Medicare patients
190
Services billed
1,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$106,750
EliquisApixaban366$100,923
XifaxanRifaximin37$59,319
DovatoDolutegravir Sodium/Lamivudine11$34,031
JardianceEmpagliflozin110$33,631
MyrbetriqMirabegron115$26,247
XareltoRivaroxaban94$23,434
Bydureon BciseExenatide Microspheres26$23,034
Paliperidone ErPaliperidone12$15,844
FarxigaDapagliflozin Propanediol54$14,990
SantylCollagenase Clostridium Hist.15$13,785
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog65$13,432
LinzessLinaclotide21$12,017
NuedextaDextromethorphan Hbr/Quinidine25$12,005
JanuviaSitagliptin Phosphate41$11,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$18$12,00525 claims
NovartisEntresto$12$11,30934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 275 geriatric medicine providers in Texas.

Other geriatric medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →